



NOVACYT RECEIVES APPROVAL IN CHINA FOR NOVAPREP®

Paris, France and Cambridge, UK – 25th February, 2015 – Novacyt (ALTERNEXT: ALNOV), an international specialist in cancer and infectious disease diagnostics, has received approval for its new consumable NOVAPrep® HQ+ orange from the China Food and Drug Administration (CFDA).

The CFDA has approved the NOVAPrep® HQ+ orange consumable which includes a new medium that better preserves the cervical samples for cytology and also for HPV testing. This follows the CFDA approval of the NOVAPrep® platform in 2014 and completes the necessary regulatory approvals for Novacyt to expand into the highly significant Chinese oncology diagnostics market.

The NOVAPrep® HQ+ orange sample preservation consumable has a number of advantages over traditional liquid based cytology consumables. Its unique design improves the sensitivity and specificity of collected samples, while the new medium provides excellent stability ensuring samples are neither damaged nor degraded prior to testing which is a significant advantage for HPV reflex testing.

Graham Mullis, Group CEO of Novacyt, commented: "With NOVAPrep® HQ+ orange now approved in China, we are ready to commercialise NOVAPrep® into this rapidly expanding cytology market which is forecast to be the largest cytology market in the world during the next five years. I look forward to updating everyone with our plans for this important market in due course."

The approval of the platform and the consumable follows a series of new developments for Novacyt since its merger with Lab21 in 2014. Since then, it has delivered strong double digit sales growth in 2014, raised €3.1 million, expanded in new markets, including the Far East and Middle East, and secured new patents for NOVAPrep® to maintain its strong proprietary and competitive position in the cytology market.

- Ends -

About Novacyt Group

The Novacyt Group is a leader in the field of cellular diagnostics with a growing portfolio of cancer and infectious disease products and services. Through its proprietary technology platform NOVAPrep® and a strong international network, Novacyt is able to provide an extensive range of oncology and infectious disease diagnostic products. The Group has diversified sales from diagnostic reagents used in oncology, microbiology, haematology and serology markets, and its global customers and partners include major corporates.

Novacyt is listed on Alternext Paris - ISIN: FR0010397232 – Ticker: ALNOV

For more information please refer to the website: www.novacyt.com



Contacts:

International Investor & Media

Tony Stephenson
Exitus Communications
+44 (0) 7899 796655
tony@exituscommunications.co.uk

French Investor & Media

Sophie Boulila / Emmanuel Huynh
Newcap,
+33 (0) 1 44 71 94 91
novacyt@newcap.fr

Novacyt

Graham Mullis
Chief Executive Officer
+44 (0) 7901 514121
graham.mullis@novacyt.com